Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Homoharringtonine vs Hydroxyurea in Interferon-Refractory CML
NCT00004933Phase 3Terminated
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jan 2000
- Primary completion
- May 2001
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of homoharringtonine in chronic myeloid leukemia (CML), sponsored by Cancer and Leukemia Group B. Started Jan 2000; status: terminated.
02
Drugs
homoharringtonine
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00004933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004933.